Tuesday, March 17, 2026

South Korea And China Focus On Strengthening Ties Rather Than Resolving Issues… Agree On Coordination For North Korean Affairs

South Korea and China strengthen ties in a recent summit, focusing on cooperation while managing sensitive issues like North Korea.

U.S. Stock Market Plunges: What SK Hynix and Samsung’s Decline Means for Asian Investors

The New York stock market faced declines, impacting major stocks like SK Hynix and Samsung, amid concerns over monetary policies.

50-Year-Old Man Sentenced for Repeated Attempts to Import Illegal Firearms

© News1 DB A man in his 50s who tried to import unauthorized air guns and parts has been sentenced to prison...

Tag: Samsung Biologics

North KoreaKoreaKimMilitarySouth KoreaAIrelationsmarketInternational

Samsung Biologics Partners with Eli Lilly: How This Open Innovation Hub Will Transform K-Bio by 2027

Samsung Biologics partners with Eli Lilly to create a biotech innovation hub in Korea, enhancing growth opportunities for local firms.

Samsung Biologics CEO John Rim Poised for Third Term: What This Means for the Global CDMO Market in 2026

John Rim of Samsung Biologics aims for a third term, leading record growth and expansion into next-gen therapies amid global challenges.

Samsung Biologics: How a 56 Billion USD CDMO Leader is Shaping the Future of Biopharmaceuticals

Samsung Biologics is evolving as a leading CDMO, targeting a production capacity of 1.32M liters by 2030 after its spin-off from Bioepis.

Samsung Biologics Joins CEPI: How This Partnership Will Revolutionize Vaccine Production in Asia

Samsung Biologics partners with CEPI to enhance vaccine manufacturing, aiming to strengthen global health security and support local biotech growth.

Samsung Biologics Partners with CEPI: A Game-Changer for Global Vaccine Production

Samsung Biologics partners with CEPI to enhance vaccine production for pandemics, aiming for rapid global supply and health security.

Samsung Biologics Earns EcoVadis Platinum: What Joining the Top 1% Signals for Global Pharma Supply Chains

Samsung Biologics achieves Platinum rating from EcoVadis, recognizing its top-tier ESG performance in sustainability and corporate responsibility.

Samsung Biologics Unveils Three-Pillar Growth Strategy: How Capacity, Portfolio, and Global Expansion Shape 2026

Samsung Biologics outlines a growth strategy focused on production, portfolio, and global expansion to enhance its CDMO position.

Global Pharma Giants Join Samsung Biologics in Major Climate Pledge to Cut Supply-Chain Emissions by 2030

Samsung Biologics leads a global initiative to reduce carbon emissions in healthcare, aiming for sustainability and renewable energy by 2030.

GAME OVER: Samsung Biologics Declares War With ‘ExellenS’—A Standard That Kills All Biotech Competition

Samsung Biologics launches ExellenS in Europe, enhancing biopharmaceutical production with standardized quality and efficiency.

Samsung Biologics Targets Japan’s $12.3 Billion CDMO Market: What You Need to Know

Samsung Biologics expands in Japan, targeting top pharma firms with new CMO brand 'ExellenS' and enhancing production capabilities.

Samsung Launches New Mini-Organ Tech to Speed Up Cancer Drug Testing

Samsung Biologics launches Samsung Organoids for drug screening, focusing on anticancer candidates to enhance precision and reduce costs.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.